Business Description
Amcad Biomed Corp
ISIN : TW0004188008
Description
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, a software solution for thyroid nodules analysis; AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals; AmCAD- U.S, a software device for viewing and quantifying ultrasound image data of backscattered signals; and AmCAD-UO offers detection for obstructive sleep apnea on awake patients to identify the root cause of sleep apnea. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.81 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 22.78 | |||||
| Beneish M-Score | -1.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.6 | |||||
| 3-Year EBITDA Growth Rate | -3.1 | |||||
| 3-Year EPS without NRI Growth Rate | -8.4 | |||||
| 3-Year FCF Growth Rate | 6 | |||||
| 3-Year Book Growth Rate | -8.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.34 | |||||
| 9-Day RSI | 23.31 | |||||
| 14-Day RSI | 27.76 | |||||
| 6-1 Month Momentum % | 37.87 | |||||
| 12-1 Month Momentum % | 75.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.35 | |||||
| Quick Ratio | 12.32 | |||||
| Cash Ratio | 11.76 | |||||
| Days Inventory | 372.18 | |||||
| Days Sales Outstanding | 38.97 | |||||
| Days Payable | 14.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.87 | |||||
| Operating Margin % | -82.73 | |||||
| Net Margin % | -69.44 | |||||
| FCF Margin % | -64.2 | |||||
| ROE % | -11.24 | |||||
| ROA % | -8.55 | |||||
| ROIC % | -26.09 | |||||
| ROC (Joel Greenblatt) % | -46.21 | |||||
| ROCE % | -8.5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 20.27 | |||||
| PB Ratio | 3.45 | |||||
| Price-to-Tangible-Book | 4.28 | |||||
| EV-to-EBIT | -24.19 | |||||
| EV-to-EBITDA | -40.73 | |||||
| EV-to-Revenue | 15.95 | |||||
| EV-to-FCF | -24.73 | |||||
| Price-to-Net-Current-Asset-Value | 6.77 | |||||
| Price-to-Net-Cash | 8.47 | |||||
| Earnings Yield (Greenblatt) % | -4.13 | |||||
| FCF Yield % | -3.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amcad Biomed Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 65.256 | ||
| EPS (TTM) (NT$) | -0.845 | ||
| Beta | 0.35 | ||
| Volatility % | 54.07 | ||
| 14-Day RSI | 27.76 | ||
| 14-Day ATR (NT$) | 0.922426 | ||
| 20-Day SMA (NT$) | 27.515 | ||
| 12-1 Month Momentum % | 75.16 | ||
| 52-Week Range (NT$) | 15.6 - 37.4 | ||
| Shares Outstanding (Mil) | 53.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amcad Biomed Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amcad Biomed Corp Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amcad Biomed Corp Frequently Asked Questions
What is Amcad Biomed Corp(ROCO:4188)'s stock price today?
The current price of ROCO:4188 is NT$27.10. The 52 week high of ROCO:4188 is NT$37.40 and 52 week low is NT$15.60.
When is next earnings date of Amcad Biomed Corp(ROCO:4188)?
The next earnings date of Amcad Biomed Corp(ROCO:4188) is .
Does Amcad Biomed Corp(ROCO:4188) pay dividends? If so, how much?
Amcad Biomed Corp(ROCO:4188) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers